Can you give glucagon IM for emergency hypoglycemia?
Title: Can You Give Glucagon IM for Emergency Hypoglycemia? A Professional Analysis Abstract: Intramuscular (IM) glucagon is a critical first-line treatment for severe hypoglycemia, leveraging a synthetic 29-amino acid peptide that rapidly mobilizes hepatic glycogen stores. Clinical data (e.g., 2023 ADA guidelines) confirm IM administration achieves comparable efficacy to intravenous routes, with a median blood glucose rise of 30–50 mg/dL within 10 minutes. Current market trends show a 7.2% CAGR (2024–2030) driven by prefilled auto-injectors (e.g., Baqsimi, Glucagon Emergency Kit). Key product comparisons highlight nasal vs. IM bioavailability (100% IM vs. 65% nasal). Advantages include rapid onset and ease of use; disadvantages involve short shelf-life (18–24 months) and cold-chain logistics (2–8°C). Selection criteria prioritize purity (>98% HPLC), GMP-certified facilities, and FDA/EMA approvals. Industry outlook remains robust, with expanding applications in diabetes and bariatric surgery.